Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NEWBRY.STthis companyNewbury Pharmaceuticals AB (publ)	SEK 1.70	-3.35×	0×	1.79×	0×	-52637.2%	24.8%	-48.4%	-53.7%	0.0%	0.0%	0.0%	0×	0×	0×	0×	0.0%	1	0.45	1	D+
ACOU.STAcouSort AB	SEK 3.12	-4.42×	3.27×	7.79×	-3.29×	-1703.2%	-211.6%	-211.6%	-177.3%	-74.6%	-89.0%	-32.4%	0×	0.44×	-10.85×	8.19×	0.0%	2	-4.93	1	D+
EXPRS2.STExpreS2ion Biotech Holding AB (publ)	SEK 0.91	-1.19×	1.27×	12.37×	0×	1336.2%	-1171.5%	-1444.4%	-1041.4%	-106.7%	-121.9%	-90.4%	0.06×	0.88×	-117.12×	2.04×	0.0%	2	-2.66	3	B
HEART.STScandinavian Real Heart AB (Publ)	SEK 16.40	-1.96×	1.11×	0×	-3.8×	-85.9%	0.0%	0.0%	0.0%	-56.8%	-22.9%	-23.8%	0.07×	0.8×	-41.14×	2.5×	0.0%	3	8.38	2	C
ODI.STODI Pharma AB	SEK 1.33	21.82×	18.52×	1.34×	15.65×	-2478.3%	31.2%	7.6%	6.0%	83.7%	105.4%	10.4%	0×	-1.31×	4.15×	1.81×	0.0%	6	13.25	3	B-
ONCOZ.STOncoZenge AB (publ)	SEK 3.30	-5.16×	-139.7×	30.78×	-5.41×	-72.6%	-181.7%	-595.7%	-598.3%	2715.5%	-229.6%	-15.9%	-12.78×	-0.24×	-93.91×	1.01×	0.0%	2	-18.16	2	C
Peer median	—	-1.96×	1.27×	7.79×	-3.29×	-85.9%	-181.7%	-211.6%	-177.3%	-56.8%	-89.0%	-23.8%	0×	0.44×	-41.14×	2.04×	0.0%	2	-2.66	2	—